Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
John Wiley & Sons Q1 2027 Earnings Call: Complete Transcript
John Wiley & Sons (NYSE:WLY) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This content is powered by Benzinga APIs.
John Wiley & Sons (WLY) Beats Q1 Earnings and Revenue Estimates
John Wiley & Sons reported Q3 2026 earnings of $0.44 per share, beating consensus estimates of $0.40, with a 10% earnings surprise. However, revenues of $386.36 million slightly exceeded expectations while declining year-over-year. The stock has surged 66.7% year-to-date but carries a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. The Publishing - Books industry ranks in the bottom 3% of Zacks industries, presenting significant headwinds for future performance.
John Wiley & Sons Affirms FY2027 Adj EPS Guidance of $4.60-$5.05 vs $4.80 Est
John Wiley & Sons (NYSE:WLY) affirms FY2027 Adj EPS guidance from $4.60-$5.05 to $4.60-$5.05 vs $4.80 analyst estimate..